The KRAS G13D mutation conveys sensitivity to EGFR inhibitors in preclinical models, and retrospective clinical reports suggested possible treatment benefit with cetuximab similar to KRAS wild-type CRC. This evidence concerns the gene KRAS and colorectal carcinoma.